Tessa Therapeutics
- Company typePrivate
- Founded2001
- HeadquartersSingapore, Singapore
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
Tessa Therapeutics firmographics
Firmographics- Name
- Tessa Therapeutics
- Website
- https://tessacell.com
- Company type
- Private
- Founded year
- 2001
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Ownership category
- akta.pro rank
Tessa Therapeutics industry classification
Industry- Product category
- Cell Therapy
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- CAR-T & TCR-T Therapies (HLAAABAC)
- akta.pro secondary industries
- Cell Therapy Developers (Autologous) (HLAAABAA), Dendritic Cell & Other APC-based Therapies (HLAAABAF), Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL), Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies) (HLAAANAK)
Keywords
Where Tessa Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Singapore
- HQ country
- Singapore
- HQ region
- Asia
Markets served
Tessa Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Infrastructure
Tessa Therapeutics product offering
Product offeringCore offering
Tessa Therapeutics develops autologous T cell-based immunotherapies designed to treat solid tumors. The company's platform leverages virus-specific T cells and related cell engineering approaches to create patient-specific cell therapies for oncology indications. Operations span clinical development, cell therapy manufacturing, and translational research from its Singapore base.
Differentiator
Problem solved
Functional benefit
Products and services
- Autologous T cell therapy for solid tumors
Companies that use Tessa Therapeutics
Customer profileIdeal customer profiles2 records
Tessa Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Tessa Therapeutics partnerships and signals
Strategic signalScale indicators1 record
Recent moves2 records
Expansion highlights4 records
Tessa Therapeutics competitors and assessment
Company assessmentDirect peers
- Adaptimmune Therapeutics: Adaptimmune develops SPEAR T cell receptor (TCR-T) therapies for solid tumors, directly overlapping with Tessa's T cell receptor approach. Both target solid tumor indications using engineered autologous T cells.
- Iovance Biotherapeutics: Iovance develops tumor-infiltrating lymphocyte (TIL) therapies for solid tumors, the closest direct competitor to Tessa's autologous T cell platform. Both companies target the same unmet need of cell therapy for solid tumors.
- Sorrento Therapeutics: Sorrento is developing CAR-T and other cell therapy approaches including for solid tumors. Its diversified pipeline includes directly comparable autologous cell therapy programs.
- Marker Therapeutics: Marker Therapeutics develops multi-tumor-associated antigen-specific T cell therapies for solid tumors and hematologic malignancies. Its non-engineered, multi-antigen T cell platform overlaps conceptually with Tessa's T cell approach.
Broad incumbents
- Fate Therapeutics: Fate Therapeutics is a leader in iPSC-derived off-the-shelf NK and T cell therapies. It is a broader cell therapy incumbent pursuing off-the-shelf alternatives to Tessa's autologous T cell strategy.
- Allogene Therapeutics: Allogene is a leading allogeneic CAR-T developer with a broad pipeline across hematologic and solid tumors. It is a broader incumbent in cell therapy whose off-the-shelf approach contrasts with Tessa's autologous strategy.
Regional players
- Carsgen Therapeutics: Carsgen is a China-based CAR-T developer with solid tumor programs, comparable to Tessa in modality and target indication. It serves primarily the APAC market and provides regional competitive context.
- Takara Bio: Takara Bio is a Japan-based cell therapy and gene therapy developer with engineered T cell programs. It is a regional peer with comparable cell therapy capabilities in the APAC market where Tessa operates.
Emerging players
- Cellectis: Cellectis develops allogeneic CAR-T therapies using TALEN gene editing. It is an emerging player in engineered cell therapy that overlaps with Tessa's cell engineering approach but with an allogeneic rather than autologous focus.
- Tmunity Therapeutics: Tmunity develops next-generation CAR-T and engineered T cell therapies, including programs in solid tumors. It is an emerging player in the same engineered T cell space as Tessa.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks5 records
Key highlights7 records
Customer concentration
Tessa Therapeutics social profiles
Digital presenceTessa Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Tessa Therapeutics leadership team
Management profileNumber of profiles
Profiles1 record
Tessa Therapeutics funding detail
Funding detailFunding overview
Funding rounds5 records
Investors8 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Tessa Therapeutics M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Tessa Therapeutics
What does Tessa Therapeutics do?
Tessa Therapeutics develops autologous T cell-based immunotherapies designed to treat solid tumors. The company's platform leverages virus-specific T cells and related cell engineering approaches to create patient-specific cell therapies for oncology indications. Operations span clinical development, cell therapy manufacturing, and translational research from its Singapore base.
Is Tessa Therapeutics a public or private company?
Tessa Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.
When was Tessa Therapeutics founded?
Tessa Therapeutics was founded in 2001. It employs 101 to 250 people.
Where is Tessa Therapeutics based?
Tessa Therapeutics is headquartered in Singapore, Singapore, in the Asia region.
Who are Tessa Therapeutics's main competitors?
Direct peers on record are Adaptimmune Therapeutics, Iovance Biotherapeutics, Sorrento Therapeutics and Marker Therapeutics. Broad incumbents are Fate Therapeutics and Allogene Therapeutics. Regional players are Carsgen Therapeutics and Takara Bio. Emerging players are Cellectis and Tmunity Therapeutics.
Does Tessa Therapeutics have an API?
No public API is recorded for Tessa Therapeutics.
What industry is Tessa Therapeutics in?
Tessa Therapeutics's product category is Cell Therapy. Its primary akta.pro industry code is HLAAABAC, CAR-T & TCR-T Therapies, with a secondary code of HLAAABAA, Cell Therapy Developers (Autologous). Its NAICS code is 325414 and its SIC code is 2836.